Business Wire
– Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secondary endpoints in patient... Read more.
Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean in... Read more.
University of Phoenix alumna, Dr. Rose Lorenzo, serves as CEO of Hackathon Jr. PHOENIX–(BUSINESS WIRE)–University of Phoenix is pleased to announce ... Read more.
BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duratio... Read more.
SVTA Welcomes New Members Yospace, Cadami, Akamai, and DAZN as Well as Numerous DASH-IF Members Participating in the Q3 Member Meeting in Antwerp, Belgium on Se... Read more.
This joint offering allows operators to benefit from seamless, high-quality streaming, extended device reach, and advanced advertising and security features AMS... Read more.
KEYTRUDA is the first anti-PD-1/L1 therapy in combination with trastuzumab and chemotherapy to demonstrate a statistically significant improvement in OS in this... Read more.
Tumors shrank in 89% of taletrectinib-treated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who were tyrosine kinase inhibitor... Read more.
Updated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a promising 45% overall response rate (ORR), ... Read more.
Comprehensive Smartwatch Reference Platform to Include Key Hardware and Software Components, Including Industry-leading Masimo Biosensing Capabilities IRVINE, C... Read more.